These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9855318)

  • 21. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
    Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
    J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
    Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
    J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
    Fletcher CV; Brundage RC; Remmel RP; Page LM; Weller D; Calles NR; Simon C; Kline MW
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1029-34. PubMed ID: 10722507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.
    Burger DM; Hoetelmans RM; Hugen PW; Mulder JW; Meenhorst PL; Koopmans PP; Brinkman K; Keuter M; Dolmans W; Hekster YA
    Antivir Ther; 1998; 3(4):215-20. PubMed ID: 10682141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indinavir concentrations and antiviral effect.
    Acosta EP; Henry K; Baken L; Page LM; Fletcher CV
    Pharmacotherapy; 1999 Jun; 19(6):708-12. PubMed ID: 10391416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
    Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
    J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.
    Lee LS; Panchalingam A; Yap MC; Paton NI
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4476-8. PubMed ID: 15504888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.
    Piscitelli SC; Formentini E; Burstein AH; Alfaro R; Jagannatha S; Falloon J
    Pharmacotherapy; 2002 May; 22(5):551-6. PubMed ID: 12013352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Fischl MA; Collier A; Feinberg J; Ribaudo H; DiFrancecso R; Morse GD;
    Antimicrob Agents Chemother; 2004 Mar; 48(3):918-23. PubMed ID: 14982784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients.
    Brinkman K; Kroon F; Hugen PW; Burger DM
    AIDS; 1998 Mar; 12(5):537. PubMed ID: 9543457
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.
    Zala C; Alexander CS; Ochoa C; Guillemi S; Ting LS; Bonner S; Cahn P; Harrigan PR; Montaner JS
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):363-4. PubMed ID: 15735458
    [No Abstract]   [Full Text] [Related]  

  • 36. Coadministration of milk thistle and indinavir in healthy subjects.
    DiCenzo R; Shelton M; Jordan K; Koval C; Forrest A; Reichman R; Morse G
    Pharmacotherapy; 2003 Jul; 23(7):866-70. PubMed ID: 12885100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability in activity of hepatic CYP3A4 in patients infected with HIV.
    Slain D; Pakyz A; Israel DS; Monroe S; Polk RE
    Pharmacotherapy; 2000 Aug; 20(8):898-907. PubMed ID: 10939550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
    Launay O; Tod M; Louchahi K; Belarbi L; Bouchaud O; Mémain N; Petitjean O; Robineau M; Guillevin L; Lortholary O
    Antimicrob Agents Chemother; 2004 Feb; 48(2):632-4. PubMed ID: 14742224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible reduction in indinavir serum concentrations by bosentan.
    Beau-Salinas F; Garot D; Le Guellec C; Jonville-Béra AP; Ingremeau V; Autret-Leca E
    Ther Drug Monit; 2005 Dec; 27(6):822-3. PubMed ID: 16306862
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of azithromycin on the pharmacokinetics of indinavir.
    Foulds G; LaBoy-Goral L; Wei GC; Apseloff G
    J Clin Pharmacol; 1999 Aug; 39(8):842-6. PubMed ID: 10434237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.